<DOC>
	<DOCNO>NCT01324310</DOCNO>
	<brief_summary>The purpose study evaluate effect safety multiple dose ketoconazole pharmacokinetics romidepsin single intravenous ( IV ) infusion .</brief_summary>
	<brief_title>Influence Ketoconazole Pharmacokinetics Romidepsin Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1 . Males females 18 year age old time signing informed consent document . 2 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Must diagnosis advance malignancy must fail available therapy consider standard care disease . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Negative urine serum pregnancy test female childbearing potential ; 7 . All female childbearing potential must use effective barrier method contraception ( either intrauterine contraceptive device [ IUCD ] double barrier method use condom diaphragm plus spermicide ) treatment period least 1 month thereafter . Male subject use barrier method contraception treatment period least 3 month thereafter . Female subject avoid use estrogencontaining contraceptive , since romidepsin may reduce effectiveness estrogencontaining contraceptive . An vitro binding assay determine romidepsin competes βestradiol bind estrogen receptor . 1 . Any significant medical condition psychiatric illness would prevent subject participate study . 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Subjects significant gastrointestinal disease may impair drug absorption , subject history Cohn 's disease , colectomy , gastrectomy , celiac disease , diseases know malabsorption . 4 . Serum potassium &lt; 3.8 mmol/L serum magnesium &lt; 0.85 mmol/L ( magnesium convert 2.1 mg/dl 1.7 mEq/L ) ( electrolyte abnormality correct supplementation meet inclusion criterion ) . 5 . Concomitant use drug may cause significant prolongation correct measurement time start cardiac Q wave end T wave ( QTc ) . 6 . Concomitant use Cytochrome P 450 3A4 ( CYP3A4 ) strong inhibitor within 1 week trial medication . 7 . Concomitant use CYP3A4 strong inducer within 2 week trial medication . 8 . Concomitant use therapeutic warfarin due potential drug interaction . Use low dose warfarin another anticoagulant maintain patency venous access port cannula permit . 9 . Clinically significant active infection . 10 . Known infection Human Immunodeficiency Virus ( HIV ) , hepatitis B , hepatitis C. 11 . Inadequate bone marrow organ function evidence : Hemoglobin &lt; 9 g/dL ( transfusion and/or erythropoietin permit ) ; Absolute neutrophil count ( ANC ) ≤ 1.0 * 10^9 cells/L [ subject neutropenia ( ANC 11.5 ) function disease may support granulocytecolony stimulate factor ( GCSF ) ] ; Platelet count &lt; 100 * 10^9 cells/L platelet count &lt; 75 * 10^9 cells/L bone marrow disease involvement document ; Total bilirubin &gt; 1.5 * upper limit normal ( ULN ) &gt; 2.0 * ULN presence demonstrable liver metastasis ; Serum aspartate transaminase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 1.5 * ULN &gt; 2.0 * ULN presence demonstrable liver metastasis ; Serum creatinine &gt; 2.0 * ULN ; 12 . Prior chemotherapy treatment within 3 week prior first day romidepsin treatment ( 6 week nitrosoureas ) prior treatment investigational agent within 4 week prior first day romidepsin treatment . 13 . Prior radiotherapy within 4 week prior first day treatment . Subjects fully recover whose acute toxicity relate prior radiotherapy return baseline ineligible . 14 . Major surgery within 2 week study entry ( day 1 ) . 15 . Concomitant use anticancer therapy . 16 . Concomitant use investigational agent . 17 . Prior exposure romidepsin ( histone deacetylase [ HDAC ] inhibitor allow ) . 18 . Any known cardiac abnormality , : Congenital long measure time start Q wave end T wave ( QT ) syndrome ; . Mean QTc formula ( QTcF ) interval &gt; 450 msec ; A myocardial infarction within 12 month study entry ; A history coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV . A stress image study perform subject whose cardiac status uncertain . If abnormal , angiography complete define whether CAD present . An electrocardiogram ( ECG ) record screen show evidence cardiac ischemia ( ST depression ≥ 2 mm , measure isoelectric line ST segment ) . A stress image study perform subject whose cardiac status uncertain . If abnormal , angiography complete define whether CAD present . Congestive Heart Failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition ( see Appendix F ) and/or ejection fraction &lt; 40 % multi gate acquisition ( MUGA ) scan &lt; 50 % echocardiogram and/or magnetic resonance imaging ( MRI ) ; A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , torsades de pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) ; Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥ 160/95 ; Any cardiac arrhythmia require antiarrhythmic medication 19 . Subjects pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ROMI-001</keyword>
	<keyword>romi</keyword>
	<keyword>Romidepsin</keyword>
	<keyword>Istodax</keyword>
	<keyword>advanced malignancy</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>